Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 65

1.

Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics.

Mangiafico S, Costello-Boerrigter LC, Andersen IA, Cataliotti A, Burnett JC Jr.

Eur Heart J. 2013 Mar;34(12):886-893c. doi: 10.1093/eurheartj/ehs262. Epub 2012 Aug 31. Review.

2.

Rationale and therapeutic opportunities for natriuretic peptide system augmentation in heart failure.

McKie PM, Burnett JC Jr.

Curr Heart Fail Rep. 2015 Feb;12(1):7-14. doi: 10.1007/s11897-014-0235-3. Review.

PMID:
25331110
3.

Vasopeptidase inhibition: a new concept in blood pressure management.

Burnett JC Jr.

J Hypertens Suppl. 1999 Feb;17(1):S37-43. Review.

PMID:
10340842
4.
5.

Multitarget cardiovascular drugs.

Trstenjak U, Kikelj D.

Curr Med Chem. 2011;18(17):2531-42. Review.

PMID:
21568894
6.

Vasopeptidase inhibition: a novel approach to cardiovascular therapy.

Floras JS.

Can J Cardiol. 2002 Feb;18(2):177-82. Review.

PMID:
11875587
7.

Combined neutral endopeptidase inhibitors.

Cuculi F, Erne P.

Expert Opin Investig Drugs. 2011 Apr;20(4):457-63. doi: 10.1517/13543784.2011.556617. Epub 2011 Feb 15. Review.

PMID:
21323474
8.

Vasopeptidase inhibitors: potential role in the treatment of heart failure.

Trindade PT, Rouleau JL.

Heart Fail Monit. 2001;2(1):2-7. Review.

PMID:
12634892
9.

Current role of neprilysin inhibitors in hypertension and heart failure.

von Lueder TG, Atar D, Krum H.

Pharmacol Ther. 2014 Oct;144(1):41-9. doi: 10.1016/j.pharmthera.2014.05.002. Epub 2014 May 14. Review.

PMID:
24836726
10.

Neprilysin inhibition in chronic kidney disease.

Judge P, Haynes R, Landray MJ, Baigent C.

Nephrol Dial Transplant. 2015 May;30(5):738-43. doi: 10.1093/ndt/gfu269. Epub 2014 Aug 18. Review.

11.

Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease?

Corti R, Burnett JC Jr, Rouleau JL, Ruschitzka F, L├╝scher TF.

Circulation. 2001 Oct 9;104(15):1856-62. Review.

12.

Vasopeptidase inhibition: a new direction in cardiovascular treatment.

Asher JR, Naftilan AJ.

Curr Hypertens Rep. 2000 Aug;2(4):384-91. Review.

PMID:
10981174
13.
14.

Vasopeptidase inhibitors: will they have a role in clinical practice?

Worthley MI, Corti R, Worthley SG.

Br J Clin Pharmacol. 2004 Jan;57(1):27-36. Review.

15.

Vasopeptidase inhibitors.

Weber MA.

Lancet. 2001 Nov 3;358(9292):1525-32. Review. Erratum in: Lancet 2002 Jan 12;359(9301):174.

PMID:
11705582
16.

Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances.

McMurray JJ.

Eur J Heart Fail. 2015 Mar;17(3):242-7. doi: 10.1002/ejhf.250. Review.

17.

Combined angiotensin receptor/neprilysin inhibitors: a review of the new paradigm in the management of chronic heart failure.

Macdonald PS.

Clin Ther. 2015 Oct 1;37(10):2199-205. doi: 10.1016/j.clinthera.2015.08.013. Epub 2015 Sep 17. Review.

PMID:
26386501
18.

Dual Angiotensin Receptor and Neprilysin Inhibition with Sacubitril/Valsartan in Chronic Systolic Heart Failure: Understanding the New PARADIGM.

Lillyblad MP.

Ann Pharmacother. 2015 Nov;49(11):1237-51. doi: 10.1177/1060028015593093. Epub 2015 Jul 14. Review.

PMID:
26175499
19.

Role of the natriuretic peptides in the cardiorenal and humoral actions of omapatrilat: insights from experimental heart failure.

Chen HH, Cataliotti A, Burnett JC Jr.

Curr Hypertens Rep. 2001 Dec;3 Suppl 2:S15-21. Review.

PMID:
11716801
20.

Supplemental Content

Support Center